Rheumatoid Arthritis: A Brief Overview of the Treatment

Jacqueline Bullock; Syed A A Rizvi; Ayman M Saleh; Sultan S Ahmed; Duc P Do; Rais A Ansari; Jasmin Ahmed

doi:10.1159/000493390

Rheumatoid Arthritis: A Brief Overview of the Treatment

Jacqueline Bullock
, Syed A A Rizvi
, Ayman M Saleh
, Sultan S Ahmed
, Duc P Do
, Rais A Ansari
, Jasmin Ahmed

Research output: Contribution to journal › Review article › peer-review

Abstract

Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease, affecting the joints with varying severity among patients. The risk factors include age, gender, genetics, and environmental exposure (cigarette smoking, air pollutants, and occupational). Many complications can follow, such as permanent joint damage requiring arthroplasty, rheumatoid vasculitis, and Felty syndrome requiring splenectomy if it remains unaddressed. As there is no cure for RA, the treatment goals are to reduce the pain and stop/slow further damage. Here, we present a brief summary of various past and present treatment modalities to address the complications associated with RA.

Original language	American English
Pages (from-to)	501-507
Number of pages	7
Journal	Medical principles and practice : international journal of the Kuwait University, Health Science Centre
Volume	27
Issue number	6
DOIs	https://doi.org/10.1159/000493390
State	Published - Jan 2019

Bibliographical note

Keywords

Adrenal Cortex Hormones
Analgesics
Anti-Inflammatory Agents
Antibodies
Antirheumatic Agents
Arthritis
Humanized
Humans
Immunosuppressive Agents
Interleukin 1 Receptor Antagonist Protein
Leflunomide
Monoclonal
Non-Steroidal
Opioid
Physical Therapy Modalities
Rheumatoid
Risk Factors
Tumor Necrosis Factor-alpha
Adrenal Cortex Hormones/adverse effects
Anti-Inflammatory Agents, Non-Steroidal/adverse effects
Tumor Necrosis Factor-alpha/therapeutic use
Antibodies, Monoclonal, Humanized/therapeutic use
Arthritis, Rheumatoid/complications
Analgesics, Opioid/therapeutic use
Interleukin 1 Receptor Antagonist Protein/therapeutic use
Antirheumatic Agents/adverse effects
Immunosuppressive Agents/therapeutic use
Leflunomide/therapeutic use
Boutonnière deformity
Rheumatoid arthritis
Swan neck deformity

Disciplines

Medicine and Health Sciences
Pharmacy and Pharmaceutical Sciences

Access to Document

10.1159/000493390License: CC BY-NC

Cite this

@article{84f368eabcd74d72ab42829dfd62ef70,

title = "Rheumatoid Arthritis: A Brief Overview of the Treatment",

abstract = " Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease, affecting the joints with varying severity among patients. The risk factors include age, gender, genetics, and environmental exposure (cigarette smoking, air pollutants, and occupational). Many complications can follow, such as permanent joint damage requiring arthroplasty, rheumatoid vasculitis, and Felty syndrome requiring splenectomy if it remains unaddressed. As there is no cure for RA, the treatment goals are to reduce the pain and stop/slow further damage. Here, we present a brief summary of various past and present treatment modalities to address the complications associated with RA.",

keywords = "Adrenal Cortex Hormones, Analgesics, Anti-Inflammatory Agents, Antibodies, Antirheumatic Agents, Arthritis, Humanized, Humans, Immunosuppressive Agents, Interleukin 1 Receptor Antagonist Protein, Leflunomide, Monoclonal, Non-Steroidal, Opioid, Physical Therapy Modalities, Rheumatoid, Risk Factors, Tumor Necrosis Factor-alpha, Adrenal Cortex Hormones/adverse effects, Anti-Inflammatory Agents, Non-Steroidal/adverse effects, Tumor Necrosis Factor-alpha/therapeutic use, Antibodies, Monoclonal, Humanized/therapeutic use, Arthritis, Rheumatoid/complications, Analgesics, Opioid/therapeutic use, Interleukin 1 Receptor Antagonist Protein/therapeutic use, Antirheumatic Agents/adverse effects, Immunosuppressive Agents/therapeutic use, Leflunomide/therapeutic use, Boutonni{\`e}re deformity, Rheumatoid arthritis, Swan neck deformity",

author = "Jacqueline Bullock and Rizvi, \{Syed A A\} and Saleh, \{Ayman M\} and Ahmed, \{Sultan S\} and Do, \{Duc P\} and Ansari, \{Rais A\} and Jasmin Ahmed",

note = "{\textcopyright} 2018 The Author(s) Published by S. Karger AG, Basel.",

year = "2019",

month = jan,

doi = "10.1159/000493390",

language = "American English",

volume = "27",

pages = "501--507",

journal = "Medical principles and practice : international journal of the Kuwait University, Health Science Centre",

issn = "1011-7571",

number = "6",

}

TY - JOUR

T1 - Rheumatoid Arthritis: A Brief Overview of the Treatment

AU - Bullock, Jacqueline

AU - Rizvi, Syed A A

AU - Saleh, Ayman M

AU - Ahmed, Sultan S

AU - Do, Duc P

AU - Ansari, Rais A

AU - Ahmed, Jasmin

PY - 2019/1

Y1 - 2019/1

N2 - Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease, affecting the joints with varying severity among patients. The risk factors include age, gender, genetics, and environmental exposure (cigarette smoking, air pollutants, and occupational). Many complications can follow, such as permanent joint damage requiring arthroplasty, rheumatoid vasculitis, and Felty syndrome requiring splenectomy if it remains unaddressed. As there is no cure for RA, the treatment goals are to reduce the pain and stop/slow further damage. Here, we present a brief summary of various past and present treatment modalities to address the complications associated with RA.

AB - Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease, affecting the joints with varying severity among patients. The risk factors include age, gender, genetics, and environmental exposure (cigarette smoking, air pollutants, and occupational). Many complications can follow, such as permanent joint damage requiring arthroplasty, rheumatoid vasculitis, and Felty syndrome requiring splenectomy if it remains unaddressed. As there is no cure for RA, the treatment goals are to reduce the pain and stop/slow further damage. Here, we present a brief summary of various past and present treatment modalities to address the complications associated with RA.

KW - Adrenal Cortex Hormones

KW - Analgesics

KW - Anti-Inflammatory Agents

KW - Antibodies

KW - Antirheumatic Agents

KW - Arthritis

KW - Humanized

KW - Humans

KW - Immunosuppressive Agents

KW - Interleukin 1 Receptor Antagonist Protein

KW - Leflunomide

KW - Monoclonal

KW - Non-Steroidal

KW - Opioid

KW - Physical Therapy Modalities

KW - Rheumatoid

KW - Risk Factors

KW - Tumor Necrosis Factor-alpha

KW - Adrenal Cortex Hormones/adverse effects

KW - Anti-Inflammatory Agents, Non-Steroidal/adverse effects

KW - Tumor Necrosis Factor-alpha/therapeutic use

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Arthritis, Rheumatoid/complications

KW - Analgesics, Opioid/therapeutic use

KW - Interleukin 1 Receptor Antagonist Protein/therapeutic use

KW - Antirheumatic Agents/adverse effects

KW - Immunosuppressive Agents/therapeutic use

KW - Leflunomide/therapeutic use

KW - Boutonnière deformity

KW - Rheumatoid arthritis

KW - Swan neck deformity

UR - https://nsuworks.nova.edu/hpd_corx_facarticles/77

U2 - 10.1159/000493390

DO - 10.1159/000493390

M3 - Review article

C2 - 30173215

SN - 1011-7571

VL - 27

SP - 501

EP - 507

JO - Medical principles and practice : international journal of the Kuwait University, Health Science Centre

JF - Medical principles and practice : international journal of the Kuwait University, Health Science Centre

IS - 6

ER -

Rheumatoid Arthritis: A Brief Overview of the Treatment

Abstract

Bibliographical note

Keywords

Disciplines

Access to Document

Other files and links

Fingerprint

Cite this